198 related articles for article (PubMed ID: 33100098)
1. The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients.
Yazawa M; Fülöp T; Cseprekal O; Talwar M; Balaraman V; Bhalla A; Azhar A; Kovesdy CP; Eason JD; Molnar MZ
Ren Fail; 2020 Nov; 42(1):1083-1092. PubMed ID: 33100098
[TBL] [Abstract][Full Text] [Related]
2. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
[TBL] [Abstract][Full Text] [Related]
3. CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors.
Azhar A; Tsujita M; Talwar M; Balaraman V; Bhalla A; Eason JD; Nouer SS; Sumida K; Remport A; Hall IE; Griffin R; Rofaiel G; Molnar MZ
Ren Fail; 2022 Dec; 44(1):831-841. PubMed ID: 35546431
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with hepatitis C antibody seroconversion after transplantation of kidneys from hepatitis C infected donors to hepatitis C naïve recipients.
Agbim U; Cseprekal O; Yazawa M; Talwar M; Balaraman V; Bhalla A; Podila PSB; Maliakkal B; Nair S; Eason JD; Molnar MZ
Ren Fail; 2020 Nov; 42(1):767-775. PubMed ID: 32729359
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.
Molnar MZ; Azhar A; Tsujita M; Talwar M; Balaraman V; Bhalla A; Podila PSB; Kothadia J; Agbim UA; Maliakkal B; Satapathy SK; Kovesdy CP; Nair S; Eason JD
Am J Kidney Dis; 2021 May; 77(5):739-747.e1. PubMed ID: 33333148
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.
Gupta G; Kang L; Yu JW; Limkemann AJ; Garcia V; Bandyopadhyay D; Kumar D; Fattah H; Levy M; Cotterell AH; Sharma A; Bhati C; Reichman T; King AL; Sterling R
Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28712111
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
9. Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?
Cannon RM; Locke JE; Orandi BJ; Anderson DJ; Davis EG; Mackelaite L; Dave H; Eng M; Jones CM
Transplantation; 2020 Jun; 104(6):1215-1228. PubMed ID: 31517783
[TBL] [Abstract][Full Text] [Related]
10. Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post-transplant BK and cytomegalovirus infection.
Daloul R; Schnelle K; Von Stein L; Logan A; Singh P; Yenebere P; Pesavento T; Washburn K
Transpl Infect Dis; 2022 Aug; 24(4):e13887. PubMed ID: 35752929
[TBL] [Abstract][Full Text] [Related]
11. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update.
Gordon CE; Adam GP; Jadoul M; Martin P; Balk EM
Am J Kidney Dis; 2023 Oct; 82(4):410-418. PubMed ID: 37061019
[TBL] [Abstract][Full Text] [Related]
12. Effect of Recipient Hepatitis C Status on Outcomes of Deceased Donor Kidney Transplantation.
Yuan Q; Hong S; Perez-Ortiz A; Roth E; Chang DC; Madsen JC; Elias N
J Am Coll Surg; 2020 Jun; 230(6):853-861.e3. PubMed ID: 32035979
[TBL] [Abstract][Full Text] [Related]
13. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
14. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
[TBL] [Abstract][Full Text] [Related]
15. Donor hepatitis C antibody positivity misclassifies kidney donor profile index in non-hepatitis C-infected donors: time to revise the kidney donor profile index - a retrospective cohort study.
Yazawa M; Balaraman V; Tsujita M; Azhar A; Talwar M; Bhalla A; Potukuchi PK; Eason JD; Kovesdy CP; Molnar MZ
Transpl Int; 2020 Dec; 33(12):1732-1744. PubMed ID: 32935416
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus and cancer after kidney transplantation: Role of the human leukocyte antigen system?
Wong G; Chakera A; Chapman JR; Chadban SC; Pilmore H; Craig JC; Lim WH
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27860123
[TBL] [Abstract][Full Text] [Related]
17. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.
Bowring MG; Shaffer AA; Massie AB; Cameron A; Desai N; Sulkowski M; Garonzik-Wang J; Segev DL
Am J Transplant; 2019 Aug; 19(8):2329-2341. PubMed ID: 30861279
[TBL] [Abstract][Full Text] [Related]
18. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
[TBL] [Abstract][Full Text] [Related]
19. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
